Register
Login:
Share:
Email Facebook Twitter

Fund Manager Chris Bailey talks about an opportunist 2017 for investors Watch here

Fund Manager Chris Bailey talks about an opportunist 2017 for investors


Summit Ther Share Price (SUMM)



Share Price Information for Summit Ther (SUMM)


Share Price: 157.50Bid: 155.00Ask: 160.00Change: 0.00 (0.00%)No Movement on Summit Ther
Spread: 5.00Spread as %: 3.23%Open: 157.50High: 157.50Low: 157.50Yesterday’s Close: 157.50

Summit Therapeutics Plc Ord 1P

Summit Ther is listed in the FTSE AIM All-Share
Summit Ther is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
157.50

Share Price SpacerBid
155.00

Share Price SpacerAsk
160.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
0

Share Price SpacerOpen
157.50

Share Price SpacerHigh
157.50

Share Price SpacerLow
157.50

Share Price SpacerClose
157.50

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 61.82m £97.36m 2,000

52 Week High 260.00 52 Week High Date 4-OCT-2016
52 Week Low 82.50 52 Week Low Date 4-MAR-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
0 0 0 -5.431 -29.00 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

12-Jan-17
12:17:16
163.00
5,000
Buy* 
155.00
160.00
8,150
Trade Type:
Ordinary

12-Jan-17
12:17:16
163.00
-5,000
Buy* 
155.00
160.00
-8,150
Trade Type:
Ordinary
Deletion
Late reported

12-Jan-17
17:28:16
157.50
2,500
 
0.00
0.00
3,938
Trade Type:
Ordinary
Bargain conditions apply




View more Summit Ther trades >>

Directors Deals for Summit Ther (SUMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
18-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
David Wurzer held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 David Wurzer
2.33USD7,5007500
17-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Valerie Andrews held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 Valerie Andrews
2.3USD10,50010500
16-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Frank Armstrong held the position of Non-Executive Chairman at Summit Therapeutics at the time of this trade.
 Frank Armstrong
2.34USD4,25014442
View more Summit Ther directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Fri 17:22ChrisatrdgSummit 'on the move up'157.50Strong Buy
Summit Therapeutics Plc breached its 50 day moving average in a Bullish Manner : SUMM-GB : January 12, 2017

http://www.capitalcube.com/blog/index.php/summit-therapeutics-plc-breached-its-50-day-moving-average-in-a-bullish-manner-summ-gb-january-12-2017/
Wed 20:09wingandaprayerGood start to year167.50No Opinion
£100M company heading to £1bn. Have chunks of this in each of the kids' trust funds and very excited by short and long term future.
Wed 18:21OlliehChunky money167.50Strong Buy
Today....good year ahead I feel.
Wed 14:02Free-MoneyNASDAQ - pre-market162.50No Opinion
No activity on Summit yet but Sarepta is busy and up 2% which bodes well for market open.
And what's good for the golden goose :-)

Should see some more positive trading this afternoon... fun to watch others take positions while we wait. GLA
Wed 13:05gmccDMD Clinical trial recruitment ?162.50No Opinion
Note new update on “ PoC Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With DMD (PhaseOut DMD) .

Only two sites in UK “ Active not recruiting “ First group of 24-week biopsies from PhaseOut expected to be reported Q2/Q3 2017 “ might struggle to meet that deadline unless they get a spurt on ?

USA sites : 8 locations Recruiting : UK sites 7 locations - 5 sites “ Enrolling by… Read More
Wed 11:49Free-MoneyRE: Summit SP strength mirrors SRPT165.00No Opinion
Good share price reaction on both sides of the pond.

But I see there is still a massive valuation difference between Sarepta and Summit.
Market capitalisations :

Summit : $110.53m
Sarepta : $2,149.57m

Once Ezutromid and Utrophin upregulation is proven (Q2/3) we should at least equal Sarepta in valuation but many would argue that since we can treat 100% of the population and we retain the most valuable market (US) we should exceed Sarepta's valuation. That's some upside!!!!

We… Read More

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Summit Ther (SUMM) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.